{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T14:52:05Z","timestamp":1775919125867,"version":"3.50.1"},"reference-count":167,"publisher":"Elsevier","isbn-type":[{"value":"9780128241271","type":"print"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/bs.podrm.2020.07.004","type":"book-chapter","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T08:36:15Z","timestamp":1597998975000},"page":"185-272","source":"Crossref","is-referenced-by-count":16,"title":["Irbesartan (a comprehensive profile)"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.podrm.2020.07.004_bb0010","series-title":"Martindale: The Complete Drug Reference","first-page":"1316","author":"Sweetman","year":"2009"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0015","unstructured":"ChemSpider. 2020. Website: http:\/\/www.chemspider.com\/Chemical-Structure.3618.html?rid=8d2b9c72-896d-4c6c-b31a-9a9fa16ef13c (Accessed April 6, 2020)."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0020","unstructured":"PubChem. 2020 Website: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Irbesartan#section=MeSH-Entry-Terms (Accessed April 6, 2020)."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0025","unstructured":"Drugs.Com. 2020 Website: https:\/\/www.drugs.com\/international\/irbesartan.html (Accessed April 6, 2020)."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0030","unstructured":"The Merck Index. 2020 Website: https:\/\/www.rsc.org\/Merck-Index\/monograph\/m6397\/irbesartan?q=unauthorize (Accessed April 6, 2020)."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0035","series-title":"The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals","first-page":"946","year":"2013"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0040","series-title":"N-Substituted Heterocyclic Derivatives, Their Preparation and the Pharmaceutical Compositions in Which They Are Present","author":"Claude","year":"1993"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0045","doi-asserted-by":"crossref","unstructured":"C.A. Bernhart, B.P. Ferrari, Y.A. Muneaux, J.L.A. Assens, J. Clement, F. Haudricourt, C.F. Muneaux, J.E. Taillades, M-A. Vignal, J. Gougat, P.R. Guiraudou, C.A. Lacour, A. Roccon, C.F. Cazaubon, J-C. Breliere, G.L. Fur, D. Nisato, A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists, J. Med. Chem. 36 (1993) 3371\u20133380.","DOI":"10.1021\/jm00074a018"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0050","first-page":"105","article-title":"An improved and efficient synthesis of irbesartan, an antihypertensive drug","volume":"4","author":"Rao","year":"2011","journal-title":"Org. Commun."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0055","first-page":"444","article-title":"Improved green method for synthesis of irbesartan, an antihypertensive drugs","volume":"7","author":"Singh","year":"2017","journal-title":"IJSRP"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0060","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1080\/00397910701471279","article-title":"Improved methods for the synthesis of irbesartan, an antihypertensive active pharmaceutical ingredient","volume":"37","author":"Rao","year":"2007","journal-title":"Synth. Commun."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0065","first-page":"681","article-title":"Commercial scalable process for the preparation of irbesartan intermediate","volume":"3","author":"Rao","year":"2010","journal-title":"Rasayan J. Chem."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0070","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1021\/acs.orglett.7b03719","article-title":"Synthesis of 2-aminoimidazolones and imidazolones by (3 + 2) annulation of azaoxyallyl cations","volume":"20","author":"DiPoto","year":"2018","journal-title":"Org. Lett."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0075","series-title":"One-Pot Method for Preparing Irbesartan","author":"Qin","year":"2018"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0080","series-title":"Synthesis Method of Irbesartan From Glycine Methyl Ester Hydrochloride via Acylation, Aminolysis, Selfcondensation, Alkylation and Cyclization","author":"Qiao","year":"2018"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0085","series-title":"Method for Synthesizing High-Purity Antihypertensive Drug Irbesartan","author":"Zhang","year":"2018"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0090","series-title":"Method for Preparing Irbesartan Condensate","author":"Wang","year":"2016"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0095","unstructured":"DRUGBANK. 2020 Website: https:\/\/www.drugbank.ca\/drugs\/DB01029 (Accessed April 7, 2020)."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0100","first-page":"472","article-title":"Development, evaluation and characterization of surface solid dispersion for solubility and dispersion enhancement of irbesartan","volume":"7","author":"Ganapuram","year":"2013","journal-title":"J. Pharm. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0105","first-page":"263","article-title":"Development, evaluation and characterization of surface solid dispersion for solubility and dissolution enhancement of irbesartan","volume":"4","author":"Meka","year":"2012","journal-title":"Int. J. Drug Dev. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0110","first-page":"1","article-title":"A review on analytical methods of irbesartan and its combinations in pharmaceutical dosage forms","volume":"15","author":"Nalini","year":"2019","journal-title":"Curr. Pharm. Anal."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0115","first-page":"235","article-title":"Analytical method development and validation of irbesartan: review","volume":"6","author":"Yogeesh","year":"2019","journal-title":"Eur. J. Pharm. Med. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0120","series-title":"The United States Pharmacopeia 2019: USP 41; The national Formulary: NF 36","first-page":"2358","author":"United States Pharmacopeia","year":"2019"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0125","series-title":"Council of Europe, F-67081 Strasbourg, France","author":"Pharmacopoeia","year":"2010"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0130","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ab.2010.11.024","article-title":"Electrochemical determination of antihypertensive drug irbesartan in pharmaceuticals","volume":"10","author":"Gupta","year":"2011","journal-title":"Anal. Biochem."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0135","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1080\/00032710903137491","article-title":"Quantitative analysis of irbesartan in pharmaceuticals and human biological fluids by voltammetry","volume":"42","author":"Bozal","year":"2009","journal-title":"Anal. Lett."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0140","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1590\/S0103-50532011000200008","article-title":"Voltammetry of irbesartan drug in pharmaceutical formulations and human blood: quantification and pharmacokinetic studies","volume":"22","author":"El-Desoky","year":"2011","journal-title":"J. Braz. Chem. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0145","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s11094-008-0144-4","article-title":"Adsorptive stripping voltammetric determination of irbesartan in bulk and pharmaceutical products","volume":"42","author":"Habib","year":"2008","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0150","first-page":"2805","article-title":"A review on analytical method for determination of II-receptor antagonists in different dosage forms","volume":"6","author":"Shah","year":"2015","journal-title":"J. Global Trends Pharm. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0155","first-page":"101","article-title":"Quantitative analysis method development and validation for Irbesartan in bulk drug by ultraviolet spectroscopy","volume":"4","author":"Asati","year":"2014","journal-title":"J. Adv. Pharm. Edu. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0160","first-page":"1114","article-title":"Method development, validation and stability study of irbesartan in bulk and pharmaceutical dosage form by UV-spectrophotometric method","volume":"2","author":"Pradhan","year":"2011","journal-title":"Int. J. Pharm. Biol. Arch."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0165","first-page":"1","article-title":"Estimation of irbesartan in bulk and dosage forms by new simple UV spectrophotometry using hydrotropic technique","volume":"4","author":"Nissankararao","year":"2013","journal-title":"Pharm. Anal."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0170","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s10812-019-00918-x","article-title":"Development and validation of UV-spectrophotometric method for estimation of irbesartan by the hydrotrophy technique","volume":"86","author":"Biyani","year":"2019","journal-title":"J. Appl. Spectrosc."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0175","first-page":"519","article-title":"Development and validation of analytical method for irbesartan and atorvastatin by simultaneous equation spectroscopic method","volume":"6","author":"Virani","year":"2015","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0180","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.saa.2014.04.102","article-title":"Simultaneous determination of some anti-hypertensive drugs in their binary mixture by novel spectrophotometric methods","volume":"132","author":"Fayez","year":"2014","journal-title":"Spectrochim. Acta A"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0185","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1248\/cpb.54.626","article-title":"Quantitative analysis of irbesartan in commercial dosage forms by kinetic spectrophotometry","volume":"54","author":"Rahman","year":"2006","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0190","first-page":"1674","article-title":"Simultaneous estimation of irbesartan and hydrochlorothiazide in combined pharmaceutical dosage form by UV spectroscopy","volume":"2","author":"Divya","year":"2014","journal-title":"Int. J. Innov. Pharm. Sci. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0195","first-page":"728","article-title":"Development and validation of novel UV methods for irbesartan and hydrochlorothiazide combination","volume":"3","author":"Chabukswar","year":"2010","journal-title":"Asian J. Res. Chem."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0200","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0731-7085(02)00073-0","article-title":"Determination of irbesartan in the presence of hydrochlorothiazide by derivative spectrophotometry","volume":"29","author":"Albero","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0205","first-page":"722","article-title":"Septrofluorometric, spectrophotometric and LC determination of irbesartan","volume":"3","author":"El-Bagary","year":"2011","journal-title":"J. Chem. Pharm. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0210","first-page":"1","article-title":"Analysis of eprosartan-hydrochlorothiazide and irbesartan-hydrochlorothiazide binary mixtures by derivative spectrophotometry","volume":"3","author":"Fawzy","year":"2007","journal-title":"Int. J. Appl. Chem."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0215","first-page":"543","article-title":"Three new spectrophotometric methods applied to the simultaneous determination of hydrochlorothiazide and irbesartan","volume":"58","author":"Erk","year":"2003","journal-title":"Pharmazie"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0220","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1081\/AL-120024337","article-title":"Simultaneous determination of irbesartan and hydrochlorothiazide in tablets by derivative spectrophotometry","volume":"36","author":"Joseph-Charles","year":"2003","journal-title":"Anal. Lett."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0225","first-page":"300","article-title":"Simple novel spectrophotometric and spectrofluorimetric methods for determination of some antihypertensive drugs","volume":"7","author":"Farouk","year":"2011","journal-title":"J. Am. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0230","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.farmac.2005.04.013","article-title":"Determination of hydrochlorothiazide and irbesartan in pharmaceuticals by fourth-order UV derivative spectrophotometry","volume":"60","author":"Vetuschi","year":"2005","journal-title":"IL Farmaco"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15406\/japlr.2016.02.00019","article-title":"Spectrophotometric multicomponent analysis of irbesartan, hydrochlorothiazide and ramipril in pharmaceutical formulations by chemometric techniques","volume":"2","author":"Sivasubramanian","year":"2016","journal-title":"J. Anal. Pharm. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0240","first-page":"389","article-title":"Simultaneous estimation of irbesartan and hydrochlorothiazide by UV spectroscopy","volume":"7","author":"Shakya","year":"2015","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0245","first-page":"17545","article-title":"Simultaneous determination of irbesartan and hydrochlorothiazide by spectrophotometry","volume":"8","author":"Pattanaik","year":"2016","journal-title":"Int. J. Pharm. Technol."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0250","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5530\/phm.2015.6.18","article-title":"New spectrophotometric methods for the simultaneous determination of irbesartan and hydrochlorothiazide in combined dosage forms","volume":"6","author":"Kumar","year":"2015","journal-title":"Pharm. Methods"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.22270\/ajprd.v7i3.512","article-title":"Determination of simultaneous irbesartan and hydrochlorothiazide by ultraviolet spectrophotometry with dual wavelength method","volume":"7","author":"Syahputra","year":"2019","journal-title":"Asian J. Pharm. Res. Dev."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0260","first-page":"373","article-title":"H-point standard addition method for simultaneous spectrophotometric determination of irbesartan, hydrochlorothiazide and telmisartan in tablets","volume":"4","author":"Sivasubramanian","year":"2014","journal-title":"Int. J. Res. Pharm. Chem."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0265","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.saa.2006.06.015","article-title":"Extractive-spectrophotometric determination of disopyramide and irbesartan in their pharmaceutical formulation","volume":"66","author":"Abdellatef","year":"2007","journal-title":"Spectrochim. Acta A"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0270","first-page":"1499","article-title":"Spectrophotometric and spectrofluorimetric determination of certain angiotensin receptor blockers through complex formation","volume":"3","author":"Omar","year":"2011","journal-title":"J. Pharm. Sci. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0275","first-page":"3","article-title":"Non-extractive spectrophotometric methods for determination of some angiotensin II receptor antagonists","volume":"3","author":"El-Sutohy","year":"2013","journal-title":"Asian J. Pharm. Anal."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0280","first-page":"1769","article-title":"Spectrophotometric determination of drugs using 2,3 dichloro 5,6 dicyano-p-benzoquinone as analytical reagent","volume":"3","author":"Fathima","year":"2011","journal-title":"Int. J. ChemTech Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0285","first-page":"415","article-title":"Novel 96-microwell spectrophotometric assays with high throughput for determination of irbesartan in its tablets","volume":"7","author":"Darwish","year":"2012","journal-title":"Dig. J. Nanomater. Biostruct."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0290","doi-asserted-by":"crossref","first-page":"43","DOI":"10.20510\/ukjpb\/4\/i2\/97093","article-title":"Spectrofluorimetric and spectrophotometric determination of irbesartan and bisoprolol hemifumarate independently in their tablets","volume":"4","author":"Abdelmonem","year":"2016","journal-title":"UK J. Pharm. Biosci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0295","first-page":"88","article-title":"Spectrophotometric determination of irbesartan, losartan, atenolol and hydrochlorothiazide in bulk and dosage forms","volume":"4","author":"Baraka","year":"2016","journal-title":"Asian J. Pharm. Anal. Med. Chem."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0300","first-page":"141","article-title":"Evaluating the reducing properties of some antihypertensive and antibacterial drugs, through their reaction with iron (III) ions","volume":"2","author":"Ibrahim","year":"2013","journal-title":"Anal. Chem. Ind. J."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0305","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pharma.2018.09.002","article-title":"Selective and validated kinetic spectrophotometric method for the determination of irbesartan in pure and pharmaceutical formulations","volume":"77","author":"Ashour","year":"2019","journal-title":"Ann. Pharm. Fr."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0310","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1134\/S1061934813060087","article-title":"New spectrophotometric and spectrofluorimetric methods for the determination of angiotensin II receptor antagonists in tablets and plasma","volume":"68","author":"Tekkeli","year":"2013","journal-title":"J. Anal. Chem."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0315","doi-asserted-by":"crossref","first-page":"93","DOI":"10.11648\/j.mc.20170506.12","article-title":"Sensitive extractional colorimetric analysis of fexofenadine hydrochloride and irbesartan bases through acid-dye complexation using naphthol blue black in pure form and pharmaceuticals","author":"Ashour","year":"2017","journal-title":"Modern Chem."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0320","first-page":"41","article-title":"Extractive visible spectrophotometric method for determination of telmisatan and irbesartan in bulk and pharmaceutical formulations","volume":"5","author":"Rani","year":"2012","journal-title":"Asian J. Pharm. Clin. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0325","first-page":"167","article-title":"A simple and green analytical method for determination of some angiotensin receptor antagonists by binary complex formation","volume":"14","author":"Attia","year":"2014","journal-title":"Anal. Chem. Ind. J."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0330","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jpha.2011.10.005","article-title":"Spectrofluorimetric method for determination of some angiotensin II receptor antagonists","volume":"2","author":"El-Shaboury","year":"2012","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0335","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s11426-016-5569-0","article-title":"Simultaneous determination of repaglinide and irbesartan in biological plasmas using micellar enhanced excitation-emission matrix fluorescence coupled with ATLD method","volume":"59","author":"Fu","year":"2016","journal-title":"Sci. China Chem."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0340","first-page":"1","article-title":"Development of regression analysis for determination of irbesartan in pharmaceutical tablets using fourier transform infrared spectrophotometry","volume":"1","author":"Khalid","year":"2017","journal-title":"Med. Anal. Chem. Int. J."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0345","first-page":"145","article-title":"Simultaneous determination of irbesartan and hydrochlorothiazide in tablets by CE-DAD","volume":"43","author":"Dal","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0350","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0731-7085(02)00643-X","article-title":"Simultaneous determination of hydrochlorothiazide and several angiotensin-II-receptor antagonists by capillary electrophoresis","volume":"31","author":"Hillaert","year":"2003","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0355","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/chromsci\/bmw056","article-title":"Micellar Electrokinetic chromatography (MEKC) with multiresponse chemometric optimization for the determination of hydrochlorothiazide and coformulated antihypertensives in the presence of hydrochlorothiazide major impurity","volume":"54","author":"Fayez","year":"2016","journal-title":"Chromatogr. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0360","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.chroma.2005.10.057","article-title":"Novel polymer monolith microextraction using a poly(methacrylic acid-ethylene glycol dimethacrylate) monolith and its application to simultaneous analysis of several angiotensin II receptor antagonists in human urine by capillary zone electrophoresis","volume":"1102","author":"Zhang","year":"2006","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0365","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/1522-2683(200202)23:2<223::AID-ELPS223>3.0.CO;2-T","article-title":"Application of capillary zone electrophoresis to the screening of some angiotensin II receptor antagonists","volume":"23","author":"Gonz\u00e1lez","year":"2002","journal-title":"Electrophoresis"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0370","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4103\/0250-474X.33150","article-title":"Development and validation of a HPTLC method for the simultaneous estimation of irbesartan and hydrochlorothiazide in tablet dosage form","volume":"69","author":"Shah","year":"2007","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0375","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1556\/JPC.27.2014.3.8","article-title":"Application of high-performance thin-layer chromatography for screening and simultaneous determination of some angiotensin II receptor antagonists in dosage forms and plasma","volume":"27","author":"Hussein","year":"2014","journal-title":"J. Planar Chromatogr."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0380","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2229-4708(10)11005-X","article-title":"A validated stability indicating HPTLC method for simultaneous estimation of irbesartan and hydrochlorothiazide","volume":"1","author":"Khodke","year":"2010","journal-title":"Pharm. Methods"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0385","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jtusci.2014.07.007","article-title":"High-performance thin-layer chromatography method for estimating the stability of a combination of irbesartan and amlodipine besylate","volume":"9","author":"Shah","year":"2015","journal-title":"J. Taibah Univ. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0390","doi-asserted-by":"crossref","first-page":"2","DOI":"10.15406\/japlr.2017.04.00112","article-title":"Simultaneous estimation of irbesartan, telmisartan, hydrochlorothiazide and ramipril in combined dosage forms by validated HPTLC method","volume":"4","author":"Sivasubramanian","year":"2017","journal-title":"J. Anal. Pharm. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0395","first-page":"310","article-title":"Validated HPTLC method for simultaneous estimation of irbesartan and hydrochlorthiazide in a tablet dosage form","volume":"3","author":"Rosangluaia","year":"2011","journal-title":"Der Pharma Chem."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0400","first-page":"71","article-title":"Simultaneous determination of irbesartan and hydrochlorothiazide by HPTLC method","volume":"47","author":"Mehta","year":"2010","journal-title":"Indian Drugs"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0405","doi-asserted-by":"crossref","first-page":"46","DOI":"10.53879\/id.51.07.10134","article-title":"HPTLC method development and validation for simultaneous estimation of chlorthalidone and irbesartan in combined tablet dosage form","volume":"51","author":"Kalaiselvi","year":"2014","journal-title":"Indian Drugs"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0410","first-page":"32","article-title":"Determination of irbesartan in pharmaceutical dosage forms by HPTLC","volume":"39","author":"Sane","year":"2002","journal-title":"Indian Drugs"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0415","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/10826076.2019.1585609","volume":"42","author":"Zeng","year":"2019","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0420","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1556\/JPC.28.2015.1.13","article-title":"Development of two high-performance thin-layer chromatographic methods for the determination of irbesartan in tablets and plasma","volume":"28","author":"Abd El-Rahman","year":"2015","journal-title":"J. Planar Chromatogr. Mod. TLC"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0425","doi-asserted-by":"crossref","first-page":"354","DOI":"10.5740\/jaoacint.14-179","article-title":"HPTLC with fluorescence densitometry for simultaneous determination of some angiotensin II receptor blockers in tablets and plasma","volume":"98","author":"Abd El-Rahman","year":"2015","journal-title":"J. AOAC Int."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0430","first-page":"292","article-title":"Development and validation of HPLC assay for estimation of irbesartan in human plasma","volume":"6","author":"Khanvilkar","year":"2013","journal-title":"Res. J. Pharm. Technol."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0435","first-page":"67","article-title":"RP-HPLC-DAD method for determination of irbesartan in bulk and tablets exposed to forced conditions","volume":"3","author":"Sujana","year":"2011","journal-title":"Int. J. Pharm. Res. Dev."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0440","article-title":"Content determination of irbesartan in serum by HPLC","author":"Yousheng","year":"2004","journal-title":"China Pharm."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0445","first-page":"397","article-title":"Development and validation of a sensitive RP-HPLC-PDA method for assay of irbesartan in pure and pharmaceutical dosage forms","volume":"3","author":"Prashanthi","year":"2012","journal-title":"Int. J. Pharm. Bio Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0450","first-page":"108","article-title":"Development and validation of HPLC method for the estimation of irbesartan in pharmaceutical dosage form","volume":"2","author":"Raju","year":"2011","journal-title":"Pharmacophore"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0455","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/bmc.1154","article-title":"HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies","volume":"23","author":"Bae","year":"2009","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0460","first-page":"25","article-title":"Simultaneous high-performance liquid chromatographic determination of irbesartan and hydrochlorothiazide in pharmaceutical dosage form","volume":"1","author":"Ubale","year":"2012","journal-title":"J. Pharm. Sci. Innov."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0465","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2478\/acph-2014-0014","article-title":"HPLC method with monolithic column for simultaneous determination of irbesartan and hydrochlorothiazide in tablets","volume":"64","author":"Alanazi","year":"2014","journal-title":"Acta Pharm."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0470","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jpba.2009.10.023","article-title":"Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma using HPLC coupled with tandem mass spectrometry: Application to bioequivalence studies","volume":"51","author":"Tutunji","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0475","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.3390\/molecules17033461","article-title":"Simultaneous analysis of irbesartan and hydrochlorothiazide: an improved HPLC method with the aid of a chemometric protocol","volume":"17","author":"Vuji\u0107","year":"2012","journal-title":"Molecules"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0480","first-page":"360","article-title":"Development and validation of RP-HPLC method for simultaneous estimation of irbesartan and hydrochlorothiazide in bulk and pharmaceutical dosage forms","volume":"3","author":"Hemamrutha","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0485","first-page":"29","article-title":"RP-HPLC method for the simultaneous estimation of irbesartan and hydrochlorthiazide in pharmaceutical dosage form","volume":"2","author":"Raja","year":"2012","journal-title":"Int. Res. J. Pharm. Appl. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0490","first-page":"148","article-title":"Development and validation of a RP HPLC-PDA method for simultaneous estimation of hydrochlorothiazide and irbesartan","volume":"2","author":"Chabukswar","year":"2010","journal-title":"Der. Pharm. Chem."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0495","doi-asserted-by":"crossref","first-page":"145","DOI":"10.25004\/IJPSDR.2014.060213","article-title":"Development and validation of a high performance liquid chromatography method for simultaneous determination of irbesartan and its related impurities in pharmaceutical tablets","volume":"6","author":"Prabhu","year":"2014","journal-title":"Int. J. Pharm. Sci. Drug Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0500","first-page":"94","article-title":"Development and validation of reverse phase high performance liquid chromatographymethod for simultaneous estimation of amlodipine besylate and irbesartan in synthetic mixture","volume":"2","author":"Patel","year":"2014","journal-title":"Int. J. Pharm. Drug Anal."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0505","first-page":"635","article-title":"Quantitative determination of three angiotensin-II-receptor antagonists in presence of hydrochlorothiazide by RP-HPLC in their tablet preparations","volume":"12","author":"Hafez","year":"2013","journal-title":"Iranian J. Pharm. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0510","first-page":"346","article-title":"Quantitative estimation of irbesartan in two different matrices and its application to human and dog bioavailability studies using LC-MS\/MS","volume":"8","author":"Tiwari","year":"2013","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0515","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0021-9673(01)01496-0","article-title":"Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection","volume":"949","author":"Gonzalez","year":"2002","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0520","first-page":"311","article-title":"Development and validation of RP-HPLC method for the estimation and separation of valsartan, losartan and irbesartan in bulk and pharmaceutical formulation","volume":"24","author":"Youssef","year":"2014","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0525","first-page":"831","article-title":"Identification and determination of selected angiotensin ii receptor antagonist group drugs by HPLC method","volume":"68","author":"Czerwi\u0144ska","year":"2011","journal-title":"Acta Pol. Pharm."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0530","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4103\/2231-4040.126985","article-title":"A validated stability-indicating liquid chromatographic method for determination of process related impurities and degradation behavior of irbesartan in solid oral dosage","volume":"5","author":"Goswami","year":"2014","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0535","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jchromb.2003.11.009","article-title":"Simultaneous determination of the acid\/base antihypertensive drugs celiprolol, bisoprolol and irbesartan in human plasma by liquid chromatography","volume":"801","author":"Caudrona","year":"2004","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0540","first-page":"1116","article-title":"RP-HPLC method for simultataneous determination of irbesartan, losartan, hydro-chlorothiazide and chlorthalidone-application to commercially available drug products","volume":"3","author":"Mhaske","year":"2012","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0545","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jchromb.2014.03.002","article-title":"Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by ultra high performance liquid chromatography tandem mass spectrometry and its application to a bioequivalence study","volume":"957","author":"Qiu","year":"2014","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0550","first-page":"87","article-title":"Method development and validation for estimation of irbesartan in bulk drug and pharmaceutical dosage","volume":"3","author":"Banjare","year":"2013","journal-title":"J. Drug Deliv. Ther."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0555","first-page":"696","article-title":"Development and validation of stability indicating reverse phase HPLC method for simultaneous estimation of irbesartan and hydrochlorothiazide in bulk drug and tablet dosage form","volume":"2","author":"Reddy","year":"2012","journal-title":"Int. J. Pharm. Chem. Biol. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0560","first-page":"206","article-title":"LC\/MS\/MS method for the simultaneous estimation of Losartan potassium and irbesartan in rat plasma","volume":"1","author":"Prasad","year":"2009","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0565","first-page":"476","article-title":"Novel validated chromatographic method for determination of some anti-hypertensive drugs","volume":"66","author":"Farouk","year":"2010","journal-title":"J. Am. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0570","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/bmc.2784","article-title":"Ionic liquids dispersive liquid-liquid microextraction and high-performance liquid chromatographic determination of irbesartan and valsartan in human urine","volume":"27","author":"Li","year":"2013","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0575","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/chromsci\/48.7.595","article-title":"Stability indicating LC method for simultaneous determination of irbesartan and hydrochlorothiazide in pharmaceutical preparations","volume":"48","author":"Rane","year":"2010","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0580","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1570-0232(02)00759-6","article-title":"Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by liquid chromatography","volume":"784","author":"Erk","year":"2003","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0585","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jchromb.2006.10.044","article-title":"Liquid chromatographic determination of irbesartan in human plasma","volume":"848","author":"Shakya","year":"2007","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0590","first-page":"18","article-title":"A liquid chromatography tandem mass spectrometry based method for the simultaneous determination of irbesartan and hydrochlorothiazide in human plasma","volume":"6","author":"Jain","year":"2014","journal-title":"Int. J. Drug Dev. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0595","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1002\/jssc.200900148","article-title":"Hydrophilic interaction chromatography-tandem mass spectrometric analysis of irbesartan in human plasma: application to pharmacokinetic study of irbesartan","volume":"32","author":"Lee","year":"2009","journal-title":"Sep. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0600","first-page":"740","article-title":"Method development and validation of irbesartan using LCMS\/MS: application to pharmacokinetic studies","volume":"2","author":"Ganesan","year":"2010","journal-title":"J. Chem. Pharm. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0605","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1080\/00032710903083893","article-title":"Separation and quantification of key starting materials of irbesartan using liquid chromatography-mass spectrometry as a separation and identification tool","volume":"42","author":"Reddy","year":"2009","journal-title":"Anal. Lett."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0610","first-page":"472","article-title":"RP-HPLC method development and validation for simultaneous estimation of irbesartan and hydrochlorothiazide in pharmaceutical dosage form","volume":"5","author":"Eswarudu","year":"2012","journal-title":"Asian J. Res. Chem."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0615","first-page":"1905","article-title":"Stability indicating validated related substance UFLC method & alkali degradation impurities characterized by LCMS for irbesartan in bulk and pharmaceutical formulation product","volume":"5","author":"Sathiyanarayanan","year":"2014","journal-title":"J. Glob. Trends Pharm. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0620","first-page":"1","article-title":"Irbesartan: a review on analytical method and its determination in pharmaceuticals and biological matrix","volume":"2014","author":"Virani","year":"2014","journal-title":"Pharm. Anal. Qual. Assur."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/scipharm86010001","article-title":"A fast and validated reversed-phase HPLC method for simultaneous determination of simvastatin, atorvastatin, telmisartan and irbesartan in bulk drugs and tablet formulations","volume":"86","author":"Alhazmi","year":"2018","journal-title":"Sci. Pharm."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0630","doi-asserted-by":"crossref","first-page":"70","DOI":"10.5530\/ijpi.2020.1.13","article-title":"Determination of irbesartan using stability indicating reverse phase liquid chromatographic and UV spectrophotometric method","volume":"10","author":"Mondal","year":"2020","journal-title":"Int. J. Pharm. Invest."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0635","first-page":"4531","article-title":"Development of validated stability indicating RP-HPLC method for estimation of irbesartan in bulk and pharmaceutical dosage forms","volume":"7","author":"Pradhan","year":"2016","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0640","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4172\/pharmaceutical-sciences.1000110","article-title":"Rapid stability-indicating RRLC method for simultaneous estimation of irbesartan and its related impurities","volume":"78","author":"Rao","year":"2016","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0645","first-page":"1419","article-title":"Validated RP-HPLC method for simultaneous estimation of irbesartan and hydrochlorothiazide in tablet dosage form","volume":"5","author":"Nagamani","year":"2017","journal-title":"Int. J. Pharm. Res. Health Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0650","first-page":"S333","article-title":"Development of a new validated stability indicating RP-HPLC method for the determination of irbesartan and hydrochlorothiazide","volume":"12","author":"Srinivasu","year":"2018","journal-title":"Asian J. Pharm."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0655","first-page":"32","article-title":"Gradient HPLC method for simultaneous determination of eight sartan and statin drugs in their pure and dosage forms","volume":"13","author":"Zareh","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0660","first-page":"88","article-title":"Method development and validation of irbesartan chlorthalidone and cilnidipine in their combined tablet dosage form by high performance liquid chromatography","volume":"7","author":"Dagariya","year":"2017","journal-title":"J. Drug Deliv. Ther."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0665","first-page":"64","article-title":"Development and validation of RP-HPLC method for simultaneous estimation of irbesartan and atorvastatin in synthetic mixture","volume":"11","author":"Dedhiya","year":"2017","journal-title":"J. Pharm. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0670","doi-asserted-by":"crossref","first-page":"175","DOI":"10.5958\/2231-5713.2015.00025.2","article-title":"Development and validation of RP-HPLC method for the simultaneous estimation of irbesartan and atorvastatin in synthetic mixture","volume":"5","author":"Virani","year":"2015","journal-title":"Asian J. Pharm. Technol."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0675","first-page":"1","article-title":"Quality by design approach (QbD) for the simultaneous determination of anti-hypertensive drugs (candesartan, irbesartan and hydrochlorothiazide) by RP-HPLC","volume":"4","author":"Annapurna","year":"2017","journal-title":"J. Anal. Pharm. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0680","first-page":"1017","article-title":"Stability indicating RP-HPLC method development and validation for simultaneous estimation of cilnidipine and irbesartan in its pharmaceutical dosage form","volume":"6","author":"Prajapati","year":"2017","journal-title":"World J. Pharm. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0685","first-page":"1124","article-title":"Development and validation of stability indicating chromatographic method for simultaneous estimation of cilnidipine and irbesartan in pharmaceutical dosage form","volume":"7","author":"Soni","year":"2018","journal-title":"World J. Pharm. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0690","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/jssc.201900534","article-title":"HPLC method transfer study for simultaneous determination of seven angiotensin II receptor blockers","volume":"43","author":"Marghany","year":"2020","journal-title":"J. Sep. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0695","doi-asserted-by":"crossref","first-page":"159","DOI":"10.22159\/ijap.2019v11i3.29426","article-title":"Estimation of amlodipine besylate and irbesartan in pharmaceutical formulation by RP-HPLC with forced degradation studies","volume":"11","author":"Kumar","year":"2019","journal-title":"Int. J. App. Pharm."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0700","first-page":"66","article-title":"Development and validation of HPLC method for the estimation of irbesartan in pharmaceutical dosage form","volume":"4","author":"Kavya","year":"2015","journal-title":"J. Sci. Res. Pharm."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0705","first-page":"5242","article-title":"Development and validation of HPLC method for the estimation of irbesartan","volume":"6","author":"Ingale","year":"2016","journal-title":"Indo Am. J. Pharm. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0710","first-page":"444","article-title":"Determination of irbesartan tablets and related substances by microemulsion liquid chromatography","volume":"32","author":"Zheng","year":"2016","journal-title":"Guangdong Yaoxueyuan Xuebao"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0715","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3233\/MGC-160213","article-title":"Simultaneous determination of the antihypertensives hydrochlorothiazide, losartan potassium, irbesartan and valsartan in bulk powders and pharmaceutical preparations by high performance liquid chromatography","volume":"15","author":"Hashem","year":"2016","journal-title":"Main Group Chem."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0720","first-page":"469","article-title":"Analytical method development and method validation for the estimation of irbesartan in tablet dosage form by HPLC method","volume":"4","author":"Anitha","year":"2014","journal-title":"Am. J. PharmTech Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0725","doi-asserted-by":"crossref","first-page":"273","DOI":"10.5246\/jcps.2018.04.028","article-title":"HPLC-UV method for simultaneous determination of irbesartan, candesartan, gliquidone and pioglitazone in formulations and in human serum","volume":"27","author":"Miraz","year":"2018","journal-title":"J. Chin. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0730","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10337-011-2111-6","article-title":"HPLC\u2013DAD analysis of hydrochlorothiazide and irbesartan in hypertensive patients on fixed-dose combination therapy","volume":"74","author":"Coudor\u00e9","year":"2011","journal-title":"Chromatographia"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0735","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5530\/ijper.51.2.41","article-title":"Simultaneous determination of sartans by high performance liquid chromatography with ultra violet detection","volume":"51","author":"Maslarska","year":"2017","journal-title":"Indian J. Pharm. Edu. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0740","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jfda.2015.02.008","article-title":"New ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of irbesartan in human plasma","volume":"23","author":"Wani","year":"2015","journal-title":"J. Food Drug Anal."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0745","first-page":"414","article-title":"Development and validation of bioanalytical method for simultaneous estimation of irbesartan and hydrochlorothiazide in human plasma using liquid chromatography-tandem mass spectrometry","volume":"6","author":"Patel","year":"2016","journal-title":"Int. J. Pharm. Chem. Biol. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0750","first-page":"68","article-title":"Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma using HPLC coupled with tandem mass spectrometry: application to a bioequivalence study","volume":"7","author":"Tutunji","year":"2015","journal-title":"J. Bioequiv. Availab."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0755","first-page":"96","article-title":"Determination of irbesartan and sinensetin simultaneously by liquid chromatography tandem mass spectrometry and their application to drug interaction study in rat plasma","volume":"8","author":"Nurmeilis","year":"2015","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0760","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4808","article-title":"Simultaneous quantification of candesartan and irbesartan in rabbit eye tissues by liquid chromatography-tandem mass spectrometry","volume":"34","author":"Tan","year":"2020","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0765","first-page":"853","article-title":"Development and validation of reverse phase HPLC method for determination of angiotensin receptor blocking agent irbesartan in plasma","volume":"32","author":"Nisa","year":"2019","journal-title":"Pak. J. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0770","first-page":"1733","article-title":"Determination of plasma irbesartan by HPLC-fluorescence","volume":"36","author":"Zhou","year":"2014","journal-title":"Hebei Yiyao"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0775","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jpba.2019.05.069","article-title":"An LC-MS\/MS spectrometry method for the simultaneous determination of rosuvastatin and irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies","volume":"174","author":"Elgawish","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0780","author":"Chavali"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0785","first-page":"75","article-title":"Stability indicating method development and validation of irbesartan and hydrochlorothiazide with stress degradation","volume":"3","author":"Shakeb","year":"2015","journal-title":"Int. J. Pharm. Pharm. Res."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0790","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.chemosphere.2019.02.137","article-title":"Selective determination of sartan drugs in environmental water samples by mixed-mode solid-phase extraction and liquid chromatography tandem mass spectrometry","volume":"224","author":"Castro","year":"2019","journal-title":"Chemosphere"},{"key":"10.1016\/bs.podrm.2020.07.004_bb0795","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1007\/s00216-018-1268-3","article-title":"Determination of cardiovascular drugs in sewage sludge by matrix solid-phase dispersion and ultraperformance liquid chromatography tandem mass spectrometry","volume":"410","author":"Castro","year":"2018","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0800","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11270-018-3845-7","article-title":"Development of a multi-residue method for monitoring 44 pharmaceuticals in slovene surface water by SPE-LC-MS\/MS","volume":"229","author":"Klancar","year":"2018","journal-title":"Water Air Soil Pollut."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0805","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jpba.2009.11.008","article-title":"Identification and characterization of degradation products of irbesartan using LC-MS\/TOF, MS(n), on-line H\/D exchange and LC-NMR","volume":"51","author":"Shah","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0810","doi-asserted-by":"crossref","first-page":"38","DOI":"10.22159\/2019v11i1.29037","article-title":"LC-MS\/MS study of the trace level impurities of irbesartan an angiotensin ii receptor antagonist molecule to its origin through nMS2 technique","volume":"11","author":"Saravanan","year":"2019","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0815","unstructured":"FDA, 2020. FDA Approved Drug Products: Irbesartan Oral Tablets, Highlights of PRESCRIBING INFORMATION, Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020757s069lbl.pdf (Accessed May 6, 2020)."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0820","unstructured":"FDA, 2020. FDA Approved Drug Products: Irbesartan and Hydrochlorothiazide Oral Tablets, Highlights of Prescribing Information, Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020758s073lbl.pdf (Accessed May 6, 2020)."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0825","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/j.1552-4604.1998.tb04422.x","article-title":"Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects","volume":"38","author":"Marino","year":"1998","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0830","first-page":"408","article-title":"Biotransformation of irbesartan in man","volume":"26","author":"Chando","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0835","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.2174\/092986709789057635","article-title":"Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development","volume":"16","author":"Zhou","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/bs.podrm.2020.07.004_bb0840","unstructured":"Sandoz Canada: Irbesartan Product Monograph, 2020 Available at: https:\/\/www.sandoz.ca\/sites\/www.sandoz.ca\/files\/Irbesartan%20Product%20Monograph.pdf (Accessed May 6, 2020)."}],"container-title":["Profiles of Drug Substances, Excipients and Related Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512520300169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512520300169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:34:40Z","timestamp":1761730480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871512520300169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9780128241271"],"references-count":167,"URL":"https:\/\/doi.org\/10.1016\/bs.podrm.2020.07.004","relation":{},"ISSN":["1871-5125"],"issn-type":[{"value":"1871-5125","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}